Navigation Links
VIDA Diagnostics Introduces Apollo™
Date:11/2/2010

VANCOUVER, British Columbia, Nov. 2, 2010 /PRNewswire/ -- VIDA Diagnostics, Inc., a leader in quantitative pulmonary image analysis, announces the introduction of its Apollo™ Pulmonary Evaluation Software, a comprehensive quantitative software solution for the analysis of major lung diseases, including COPD, asthma, and lung cancer, at the Chest 2010 meeting in Vancouver, BC.  

Apollo strengthens VIDA's leading quantitative pulmonary solution for lung airway and parenchymal analysis and transforms its use into a high volume, time constrained clinical and clinical trial environment.  Apollo, VIDA's first Microsoft release, has significant algorithmic, workflow and dataflow improvements applicable to clinical pulmonary disease analysis.

"We are excited to introduce our Apollo Pulmonary Evaluation Software as a transformative product for VIDA," says Susan A. Wood, Ph.D., President and CEO of VIDA Diagnostics, Inc. "Apollo advances our quantitative approach to pulmonary disease analysis by incorporating the lessons learned from our quantitative imaging experience through academic and clinical trials, and combines it with productivity and connectivity enhancements essential to its widespread clinical use."

Apollo is currently being clinically evaluated at the University of Wisconsin, and the Iowa Comprehensive Lung Imaging Center (iCLIC) at the University of Iowa where it will be used in ongoing trials to validate image-based COPD and asthma measurements.

"An evidence-based approach at the point of care will become increasingly important to the pulmonary physician in evaluating the extent and change of pulmonary disease," states J. Scott Ferguson, MD, Associate Professor, Pulmonology and Critical Care Medicine, Director of Interventional Pulmonology, University of Wisconsin, Madison. "With Apollo, performing interventions with image-guided procedures by the practicing pulmonologist is now achievable and has great potential to improve patient outcomes."

VIDA Diagnostics is currently exhibiting at Chest 2010 Annual Meeting in Vancouver, BC Booth # 1111.

About VIDA Diagnostics, Inc.

VIDA Diagnostics is a leader in quantitative pulmonary image analysis for the diagnosis and treatment of pulmonary diseases. VIDA Diagnostics develops and commercializes pulmonary applications, establishing quantitative pulmonary imaging in routine clinical practice.  VIDA is an established leader in quantitative lung analysis for COPD, emphysema and asthma, establishing objective, quantitative measures for diagnosis, interventional therapies and therapeutic response assessment.

Participating in the emerging pulmonary device market that is expected to grow to nearly $3.8 billion by 2011, VIDA's vision is to establish lung quantitative CT methods as the standard of care for diagnosis and staging of chronic lung disease. VIDA was founded by four University of Iowa faculty members, Eric Hoffman, Ph.D., Geoffrey McLennan, M.D., Ph.D., Joseph Reinhardt, Ph.D. and, Milan Sonka, Ph.D.  For more information on VIDA Diagnostics, visit: www.vidadiagnostics.com.


'/>"/>
SOURCE VIDA Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AdvaMed 2010 Sets New Attendance Record: More than 1,700 Device and Diagnostics Leaders from Across the Country and Around the World Came to Washington, D.C.
2. Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010
3. Reportlinker Adds Imaging Diagnostics Market in Poland 2010 - Development Forecasts for 2010-2012
4. Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition
5. Reportlinker Adds Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 4th Edition
6. AT&T and eCardio Diagnostics Team Up to Advance Cardiac Care Through Innovative Mobile Technology
7. Quest Diagnostics and HP Simplify Electronic Health Records for Physician Practices
8. Quest Diagnostics to Release Third Quarter 2010 Financial Results
9. Reportlinker Adds Global In Vitro Diagnostics (IVD) Market Report: 2010 Edition
10. Roche Diagnostics Supports Fight Against MRSA as a Sponsor of Annual World MRSA Day
11. Siemens Healthcare Diagnostics Publishes Global Trade Item Numbers (GTINs) for its Entire U.S. Product Line to the GHX Health ConneXion(SM) Data Pool
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016  Hologic, Inc. (Nasdaq: ... results for the fiscal second quarter ended March ... of $0.24 increased 41.2%, and non-GAAP diluted EPS ... increased 5.8% on a reported basis, and 6.3% ... "We posted another good quarter, highlighted by 14.6% ...
(Date:4/27/2016)... , April 27, 2016 ... Including 42% Growth in Recurring Consumable Sales  ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor ... announced its sales for the first quarter ended March ... and the execution of its commercial strategy. ...
(Date:4/27/2016)... Conn. , April 27, 2016   ... of its digital health technology platform, which specializes ... and programs into scalable digital products, Zillion enables ... engagement and empower consumers to take control of ... face-to-face live video conferencing – including one-to-one, group ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Memorial ... for Graduate Medical Education (ACGME) that it has received accreditation for its residency ... of three residency programs that Memorial is currently pursuing, including Pediatrics and Internal ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Bernie Siegel, ... seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death live on ... . Dr. Bernie Siegel, author of a plethora of essential books-to-read for ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a ... proud to announce one of their physicians has been invited to be a featured ... ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. Scott ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. ... for the majority of skin cancer deaths. More than 10,000 people are expected to die ... diagnosis is 62, it is the one of the most commonly diagnosed cancers in young ...
(Date:4/29/2016)... ... 29, 2016 , ... Jvion, the market leader in clinical ... Eastside Partners, with participation from existing investor Martin Ventures. The funds will ... technology and product roadmap. , “Jvion is experiencing significant growth and ...
Breaking Medicine News(10 mins):